The Effect of Exercise on Peripheral Blood Gene Expression in Angina

A Randomised Trial of the Effect of Exercise on Peripheral Blood Gene Expression in Patients With Stable Angina

Regular exercise is known to produce significant health benefits and to reduce the risk of heart diseases, although how this benefit occurs is not well understood. White blood cells are known to be involved in triggering heart attacks, and which genes are switched on or off in white blood cells determines whether they have beneficial or harmful effects. Previous studies, and studies ongoing in our group, have demonstrated measurement of peripheral blood gene expression (which reflects white blood cell gene expression) is able to distinguish between patients with and without coronary artery disease, or patients who are able to develop good compared with poor coronary collateral arteries. Therefore, the gene expression signature in peripheral blood may provide novel diagnostic or prognostic information, and insight into the pathogenesis of heart disease.

We therefore hypothesise that exercise alters peripheral blood gene expression in patients with coronary artery disease and angina. This will identify possible ways that exercise improves angina and reduces the risk of heart disease.

Study Overview

Status

Completed

Conditions

Study Type

Interventional

Enrollment (Actual)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • South Yorkshire
      • Sheffield, South Yorkshire, United Kingdom, S5 7AU
        • NIHR Cardiovascular Biomedical Research Unit

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

30 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Class I to III angina pectoris (classified according to the Canadian Cardiovascular Society [CCS])with documented myocardial ischemia or coronary artery disease on angiography
  • Ability to read and speak English to a level allowing satisfactory completion of written questionnaires and to understand instruction during the exercise programme.

Exclusion Criteria:

  • Acute coronary syndromes or recent myocardial infarction (<2 months)
  • Left main coronary artery stenosis >25% or high-grade proximal left anterior descending artery stenosis
  • Known reduced left ventricular function (ejection fraction <40%)
  • Significant valvular heart disease
  • Insulin-dependent diabetes mellitus
  • Occupational, orthopedic, and other conditions that preclude regular exercise
  • Patients whose ECG prevents interpretation of an exercise test (LBBB, RBBB, pacemaker implantation).
  • Patients who already perform greater than 30min continuous exercise three times weekly (self-reported).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: 12 week exercise training
randomised to 12 weeks of exercise training up to three times weekly. Training will be interval training with active recovery, with 3 min intervals conducted 10bpm below angina threshold.
No Intervention: Conventional Care

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Peripheral blood gene expression
Time Frame: baseline
baseline
Peripheral blood gene expression
Time Frame: 6wks after starting 12week exercise training (or conventional care)
6wks after starting 12week exercise training (or conventional care)
peripheral blood gene expression
Time Frame: 12 weeks after exercise training (or conventional care)
12 weeks after exercise training (or conventional care)
Peripheral blood gene expression
Time Frame: 24 weeks after starting 12 weeks exercise training programme
24 weeks after starting 12 weeks exercise training programme

Secondary Outcome Measures

Outcome Measure
Time Frame
Angina status
Time Frame: baseline
baseline
Angina status
Time Frame: 6wks after starting 12 week exercise programme (or conventional care)
6wks after starting 12 week exercise programme (or conventional care)
Angina status
Time Frame: 12wks after starting 12 week exercise programme (or conventional care)
12wks after starting 12 week exercise programme (or conventional care)
Angina Status
Time Frame: 24wks after starting 12 week exercise programme (or conventional care)
24wks after starting 12 week exercise programme (or conventional care)
Anxiety Score
Time Frame: baseline
baseline
Anxiety Score
Time Frame: 6wks after starting 12 week exercise programme (or conventional care)
6wks after starting 12 week exercise programme (or conventional care)
Anxiety Score
Time Frame: 12wks after starting 12 week exercise programme (or conventional care)
12wks after starting 12 week exercise programme (or conventional care)
Anxiety Score
Time Frame: 24wks after starting 12 week exercise programme (or conventional care)
24wks after starting 12 week exercise programme (or conventional care)
Depression Score
Time Frame: 6wks after starting 12 week exercise programme (or conventional care)
6wks after starting 12 week exercise programme (or conventional care)
Depression Score
Time Frame: baseline
baseline
Depression Score
Time Frame: 12wks after starting 12 week exercise programme (or conventional care)
12wks after starting 12 week exercise programme (or conventional care)
Depression Score
Time Frame: 24wks after starting 12 week exercise programme (or conventional care)
24wks after starting 12 week exercise programme (or conventional care)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2010

Primary Completion (Actual)

May 1, 2014

Study Completion (Actual)

May 1, 2014

Study Registration Dates

First Submitted

June 18, 2010

First Submitted That Met QC Criteria

June 18, 2010

First Posted (Estimate)

June 22, 2010

Study Record Updates

Last Update Posted (Estimate)

April 14, 2016

Last Update Submitted That Met QC Criteria

April 13, 2016

Last Verified

April 1, 2016

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Angina Pectoris

Clinical Trials on Structured exercise training

Subscribe